Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL29187408 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL25221364 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL8220086 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL1537423 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL3220238 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL237820 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20740843 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL21314200 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20740839 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL214838 | 0.95 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| EP-1718667-B1 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2013-01-09 | — | — | EP | claimed |
| US-7754681-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2010-07-13 | — | — | US | claimed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | claimed |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | SEAGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2024041544-A9 | A METHOD OF PREPARING AN ANTIBODY WITH SITE-SPECIFIC MODIFICATIONS | SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) | 2025-01-30 | — | — | WO | disclosed |
| US-12043670-B2 | Anti-BCMA antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| EP-4380561-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| CN-118043042-A | Conjugate comprising a covalent binding agent for targeting intracellular KRAS G12C proteins | 瑞择生物公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| WO-2020145228-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020123836-A2 | HERBOXIDIENE SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-18 | — | — | WO | disclosed |
| US-10548986-B2 | Eribulin-based antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10322192-B2 | Eribulin-based antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3423105-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | PTGS1 3816/4885SLC7A5 1184/4885ALPI 2071/4885 |
| US-10322192-B2 | Eribulin-based antibody-drug conjugates and methods of use | FOLR1, FOLR2, TUBB1 | PTGS1 4055/4885SLC7A5 1383/4885ALPI 3911/4885 |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | CTSS, CTSE, CTSL | PTGS1 4140/4885SLC7A5 510/4885ALPI 2563/4885 |
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | PTGS1 4055/4885SLC7A5 1383/4885ALPI 3911/4885 |
| US-10548986-B2 | Eribulin-based antibody-drug conjugates and methods of use | FOLR1, FOLR2, TUBB1 | PTGS1 4055/4885SLC7A5 1383/4885ALPI 3911/4885 |
| US-12043670-B2 | Anti-BCMA antibody-drug conjugates and methods of use | HNRNPM, CD79B, BCDIN3D | PTGS1 4123/4885SLC7A5 2437/4885ALPI 4559/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | PTGS1 4055/4885SLC7A5 1383/4885ALPI 3911/4885 |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | GUCY1B2, MTX2, GUCY1A2 | PTGS1 3698/4885SLC7A5 1909/4885ALPI 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.